The abstract is read at the publisher; the summary is JClub's.
Cemiplimab plus chemotherapy improves 5-year overall survival in previously untreated advanced NSCLC without EGFR, ALK, or ROS1 aberrations, with median OS 21.1 vs 12.9 months.
- Why it matters: Long-term outcomes beyond initial trial follow-up are needed to confirm durable benefit and characterize safety for first-line treatment of advanced NSCLC lacking EGFR/ALK/ROS1 alterations.
- What they did: In EMPOWER-Lung 3 part 2, 466 patients were randomized 2:1 to cemiplimab 350 mg every 3 weeks plus four chemotherapy cycles or placebo plus chemotherapy; OS, progression-free survival, and response were assessed.
- The result: After median follow-up of 60.9 months, 5-year OS probability was 19.4% vs 8.8%, with median PFS 8.2 vs 5.5 months and objective response 43.6% vs 22.1%; grade 3+ adverse events occurred in 49.4% vs 32.7%.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.